Sun Pharma secures global rights to monthly cholesterol drug; Lerodalcibep opens door to $3.7-Bn PCSK9 market
Exclusive rights outside US, China cover commercialisation and manufacturing of lerodalcibep EU-approved Lyrokaul offers once-monthly dosing and up to six ...
